Guerbet - Revenue at 30 September 2015: EU343.6 million; +10.2% at constant exchange rates
October 22 2015 - 11:12AM
Villepinte, 22 October 2015 - Guerbet (FR0000032526 GBT), a global
specialist in contrast agents and solutions for medical imaging, is
reporting third-quarter revenue up by 14.6% at constant exchange
rates. Cumulative revenue totalled €343.6 million at the end of
September 2015, up by 13.6%, or +10.2% excluding exchange rate
effects.
Consolidated Group revenue (IFRS)
In
millions of euros |
9 months 2015 |
9 months 2014 |
Change |
Q3 2015 |
Q3 2014 |
Change |
Sales in Europe |
236.7 |
214.9 |
10.1% |
78.0 |
70.9 |
9.9% |
Sales
in Other Markets |
106.9 |
87.6 |
22.1% |
38.3 |
29.0 |
32.5% |
Total |
343.6 |
302.5 |
13.6% |
116.3 |
99.9 |
16.5% |
Double-digit growth in business activity in
Europe and in Other MarketsThird-quarter sales in Europe were
€78 million, with growth of 9.9% at current exchange rates, for
total sales of €236.7 million in the first nine months of the year.
This growth in performance is once again primarily explained by
contributions from Germany, the United Kingdom, Turkey, and
Switzerland. At constant exchange rates, growth was 8.3% over the
quarter.
For Other Markets, continued higher sales in the
United States make up most of the quarter's growth. Revenue from
this part of the world totalled €38.3 million, an increase of 32.5%
for the quarter. This includes €0.7 million in positive exchange
rate effects.
Good performance from Xenetix® and
Dotarem® Sales from the MRI segment came to €53.8
million over the quarter, for growth of 28.1% compared to the 3rd
quarter of 2014. Sales of Dotarem contributed strongly to
revenue, with the rising success of Dotarem on the American
market and continued strong sales in Germany.
The X-Ray segment posted quarterly
revenue of €46.1 million. Sales benefited from a highly favourable
volume effect from Xenetix. At the end of September,
cumulative X-Ray revenue was €144.2 million (+2.8%).
Sales performance of Lipiodol® and
Patent Blue V has supported growth in the IRT segment
of more than 40% over the past nine months.
The Imaging Solutions and Services (ISS)
segment saw cumulative growth of 6.9%, for sales of €13.5
million.
Meeting annual objectivesAcquisition of
Mallinckrodt's CMDS activity should become final in the coming
weeks, pending approval of the transaction by the relevant
oversight authorities.
Following this successful third quarter, Guerbet
confirms its revenue objective, not counting acquisitions, of €445
million (+/- 2%) and its current operating margin objective
excluding acquisition-related costs (operating income/net sales) of
11% (+/- 1 point).
Upcoming events:
- Publication of 2015 annual revenue on 10 February 2016 after
trading
About Guerbet
Guerbet is a pioneer in the contrast agent
field, with nearly 90 years' experience, and is the only
pharmaceutical group dedicated to medical imaging worldwide. It
offers a comprehensive range of X-Ray, Magnetic Resonance Imaging
(MRI) and Interventional Radiology and Theranostics (IRT) products,
along with a range of injectors and related medical devices to
improve the diagnosis and treatment of patients. To discover new
products and ensure future growth, Guerbet invests heavily in
R&D, spending around 9% of its sales each year. Guerbet (GBT)
is listed on NYSE Euronext Paris (Segment B - Mid Caps) and
generated revenue of €409 million in 2014. It had a total workforce
of 1,461 employees at 31 December 2014.
For more information about Guerbet,
please go to www.guerbet.com
Contacts
Jean-François Le
MartretChief Financial Officer+33 (0)1 45 91 50 00
|
Christophe de
Lylle / Benjamin Lehari+33 (0)1 56 88 11
11cdelylle@actifin.fr / blehari@actifin.fr
PressJennifer Jullia+33 (0)1 56 88 11
19jjullia@actifin.fr |
Press release http://hugin.info/159769/R/1960884/714918.pdf
HUG#1960884
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024